Market Place
Sourcing Support
Anteris Secures CMS Reimbursement For Paradigm Trial Site
28 Apr 2026 //
GLOBENEWSWIRE
Anteris Reports 2025 Financial Results, Provides Corporate Update
26 Feb 2026 //
GLOBENEWSWIRE
Anteris to Present at TD Cowen, Barclays Conferences
23 Feb 2026 //
GLOBENEWSWIRE
Anteris Announces Strategic Investment from Medtronic
22 Jan 2026 //
GLOBENEWSWIRE
Anteris Global Corp. Completes $230M Public Stock Offering
22 Jan 2026 //
GLOBENEWSWIRE
Anteris Announces $200M Offering; Medtronic Invests
20 Jan 2026 //
GLOBENEWSWIRE
Anteris Technologies Reveals Data On 100 Duravr THV Patients
17 Nov 2025 //
GLOBENEWSWIRE
Anteris Announces Results For The Third Quarter Of 2025
12 Nov 2025 //
GLOBENEWSWIRE
Anteris DurAVR THV Shows Strong One-Year Outcomes in Small Annuli
28 Oct 2025 //
GLOBENEWSWIRE
Anteris Reveals DurAVR THV One-Year Clinical Results At TCT 2025
27 Oct 2025 //
GLOBENEWSWIRE
Anteris Treats First Patients In DurAVR® THV Global Pivotal Trial
27 Oct 2025 //
GLOBENEWSWIRE
Anteris Gets EU Nod to Begin Global DurAVR PARADIGM Trial
15 Oct 2025 //
GLOBENEWSWIRE
Anteris Tech Announces Adjournment of Stockholders Meeting
19 Sep 2025 //
GLOBENEWSWIRE
Anteris Technologies Delays Special Stockholders Meeting
11 Sep 2025 //
GLOBENEWSWIRE
Anteris Technologies Delays Special Stockholders Meeting
04 Sep 2025 //
GLOBENEWSWIRE
Anteris Reveals Q2 2025 Results
11 Aug 2025 //
GLOBENEWSWIRE
Anteris Appoints David Roberts and Gregory Moss to Board
09 Jun 2025 //
GLOBENEWSWIRE
Anteris Announces Results for the First Quarter of 2025
13 May 2025 //
GLOBENEWSWIRE
Anteris Technologies: 100 patients treated with DurAVR® THV
31 Mar 2025 //
GLOBENEWSWIRE
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
21 Mar 2025 //
GLOBENEWSWIRE
Anteris Reports 2024 Financial Results and Corporate Update
12 Mar 2025 //
GLOBENEWSWIRE
Anteris To Present At TD Cowen & Barclays Healthcare Conferences
28 Feb 2025 //
GLOBENEWSWIRE
Anteris Technologies provides update on first human study of DurAVR THV
12 Jun 2024 //
PHARMABIZ
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.